Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Durvalumab (Imfinzi)

decorative image of the issue cover

Published April 21, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Durvalumab (Imfinzi), 50 mg/mL, concentrate for IV infusion.
  • Indication: For the treatment of patients with resectable muscle invasive bladder cancer (MIBC)a in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant Imfinzi monotherapy treatment after radical cystectomy.